Zhu Sujie
Research Background
(1) Structural biology studies of tumor-related oncogenic mutations of various kinases, developing of new generation of targeted inhibitors based on the complex structure of small molecule inhibitors and target proteins.
(2) Exploration of new targets for anti-tumor and metabolic diseases, screening of corresponding targeted drugs based on multi-omics interdiscipline.
Education Background
(1) 2006.9-2010.7 obtained bachelor of science in the Jilin University
(2) 2012.9-2015.7 obtained master of science in the Peking University
(3) 2015.9-2018.7 obtained doctor of science in the Peking University
Work Experience
(1) 2010.7-2011.9 Pharmaceutical analysis researcher in CSPC
(2) 2018.7- Present Professor, Institute of Translational Medicine, College of Medicine, Qingdao University
Publication
1. Huang, L., Zhu, J., Kong, W., Li, P., and Zhu, S*. (2021). Expression and Prognostic Characteristics of m6A RNA Methylation Regulators in Colon Cancer. Int J Mol Sci 22.
2. Yan, X.E., Ayaz, P., Zhu, S.J.#, Zhao, P., Liang, L., Zhang, C.H., Wu, Y.C., Li, J.L., Choi, H.G., Huang, X., et al. (2020). Structural Basis of AZD9291 Selectivity for EGFR T790M. J Med Chem 63, 8502-8511.
3. Shen, J., Zhang, T., Zhu, S.J.#, Sun, M., Tong, L., Lai, M., Zhang, R., Xu, W., Wu, R., Ding, J., et al. (2019). Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR(L858R/T790M/C797S)). J Med Chem 62, 7302-7308.
4. Lu, X., Zhang, T., Zhu, S.J.#, Xun, Q., Tong, L., Hu, X., Li, Y., Chan, S., Su, Y., Sun, Y., et al. (2018). Discovery of JND3229 as a New EGFR(C797S) Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett 9, 1123-1127.
5. Zhu, S.J.#, Zhao, P., Yang, J., Ma, R., Yan, X.E., Yang, S.Y., Yang, J.W., and Yun, C.H. (2018). Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget 9, 13652-13665.
6. Yan, X.E., Zhu, S.J.#, Liang, L., Zhao, P., Choi, H.G., and Yun, C.H. (2017). Structural basis of mutant-selectivity and drug-resistance related to CO-1686. Oncotarget 8, 53508-53517.
7. Anastasi, S., Zhu, S.J.#, Ballaro, C., Manca, S., Lamberti, D., Wang, L.J., Alema, S., Yun, C.H., and Segatto, O. (2016). Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator. Cell 165, 1031-1034.
